Gemcitabine continuation maintenance therapy had a favourable ICER in patients with PS = @ ( @,@ / QALY ) , in responders to induction chemotherapy ( @,@ / QALY ) , regardless of histology ( adenocarcinoma , @,@ / QALY , non adenocarcinoma , @,@ / QALY ) .